Despite a challenging quarter, CRL remains optimistic about future growth with strategic acquisitions and improved funding environment.

Charles River Laboratories International, Inc. CRL reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.39, down 10.2% year over year. The figure surpassed the Zacks Consensus Estimate ...